Therapeutic cancer vaccines

Current Cancer Therapy Reviews

Volumn 6, Issue 2, 2010, Pages 163-174

  Larsen, Stine Kiær ^a   Svane, Inge Marie ^a   Straten, Per Thor ^a   Andersen, Mads Hald ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Adjuvants; Cancer; Combination therapy; Phase iii trials; Targets; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; BIOVAXID; CANCER VACCINE; CDX 110; CYCLOPHOSPHAMIDE; CYTOKINE; DCVAX; DENDRITIC CELL VACCINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; GV 1001; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; IPILIMUMAB; LUCANIX; MDX 1379; MELACINE; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MULTIKINE; PANVAC VF; PLACEBO; PREDNISONE; PROVENGE; TG 4010; THERATOPE; UNCLASSIFIED DRUG; VITESPEN;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; COLORECTAL CANCER; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DRUG MEGADOSE; DRUG POTENTIATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INNATE IMMUNITY; KIDNEY CARCINOMA; LEUKEMIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MELANOMA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; VACCINATION;

EID: 77952928999     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339410791202529     Document Type: Article

References (97)

1. Moss PA, Rosenberg WM, Bell JI. The human T cell receptor in health and disease. Annu Rev Immunol 1992; 10: 71-96.
2. Stockwin LH, McGonagle D, Martin IG, Blair GE. Dendritic cells: immunological sentinels with a central role in health and disease. Immunol Cell Biol 2000; 78(2): 91-102.
3. Jonuleit H, Schmitt E. Regulatory T-cells in antitumor therapy: isolation and functional testing of CD4+CD25+regulatory T-cells. Methods Mol Med 2005; 109: 285-96.
4. Fu YX, Chaplin DD. Development and maturation of secondary lymphoid tissues. Annu Rev Immunol 1999; 17: 399-433.
5. Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, Parmiani G. T-cell recognition of melanoma-associated antigens. J Cell Physiol 2000; 182(3): 323-31.
6. Van den Eynde BJ, Boon T. Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 1997; 27(2): 81-6.
7. Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005; 54 (3): 187-207.
8. van der BP, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254 (5038): 1643-7.
9. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17(7): 2105-16.
10. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R. Strategies for immunotherapy of cancer. Adv Immunol 2000; 75: 235-82.
11. Wolfel T, Hauer M, Schneider J, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269 (5228): 1281-4.
12. Gedde-Dahl T, III, Eriksen JA, Thorsby E, Gaudernack G. T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides. Hum Immunol 1992; 33 (4): 266-74.
13. Sharkey MS, Lizee G, Gonzales MI, Patel S, Topalian SL. CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res 2004; 64 (5): 1595-9.
14. Andersen MH, Fensterle J, Ugurel S, et al. Immunogenicity of constitutively active V599EBRaf. Cancer Res 2004; 64 (15): 5456-60.
15. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91 (9): 3515-9.
16. Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264 (5159): 716-9.
17. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
18. Houbiers JG, Nijman HW, van der Burg SH, et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993; 23(9): 2072-7.
19. Kao H, Marto JA, Hoffmann TK, et al. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001; 194 (9): 1313-23.
20. Jung S, Schluesener HJ. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 1999; 173 (1): 273-6.
21. Kyte JA, Trachsel S, Risberg B, thor SP, Lislerud K, Gaudernack G. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Cancer Immunol Immunother 2009; 58 (10): 1609-26.
22. Schmitz M, Diestelkoetter P, Weigle B, et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000; 60 (17): 4845-9.
23. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 2001; 61 (3): 869-72.
24. Andersen MH, Svane IM, Becker JC, Straten PT. The universal character of the tumor-associated antigen survivin. Clin Cancer Res 2007; 13(20): 5991-4.
25. Andersen MH, Svane IM, Kvistborg P, et al. Immunogenicity of Bcl-2 in cancer patients. Blood 2005; 15(105 Pt 2): 728-34.
26. Andersen MH, Becker JC, Straten P. Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov 2005; 4(5): 399-409.
27. Sommerfeldt N, Beckhove P, Ge Y, et al. Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. Cancer Res 2006; 66 (15): 7716-23.
28. Wenandy L, Sorensen RB, Svane IM, thor SP, Andersen MH. RhoC a new target for therapeutic vaccination against metastatic cancer. Cancer Immunol Immunother 2008; 57(12): 1871-8.
29. Luo Y, Zhou H, Krueger J, et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 2006; 116 (8): 2132-41.
30. Lee KH, Panelli MC, Kim CJ, et al. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 1998; 161(8): 4183-94.
31. Lehmann F, Marchand M, Hainaut P, et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995; 25: 340-7.
32. Pawelec G, Zeuthen J, Kiessling R. Escape from host-antitumor immunity. Crit Rev Oncog 1997; 8(2-3):111-41.
33. Riker A, Cormier J, Panelli M, et al. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 1999; 126(2): 112-20.
34. Wang Z, Seliger B, Mike N, Momburg F, Knuth A, Ferrone S. Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL29.1.22 and SK-MEL-29.1.29. Cancer Res 1998; 58(10): 2149-57.
35. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 2008; 60 (8): 915-28.
36. Ferrantini M, Capone I, Belardelli F. Dendritic cells and cytokines in immune rejection of cancer. Cytokine Growth Factor Rev 2008; 19 (1): 93-107.
37. Ferrantini M, Capone I, Belardelli F. Dendritic cells and cytokines in immune rejection of cancer. Cytokine Growth Factor Rev 2008; 19 (1): 93-107 Epub 2007 Dec 3(1:93-107): Epub.
38. Romero P, Cerottini JC, Speiser DE. Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination. Cancer Immunol Immunother 2004; 53 (3): 249-55.
39. Verdijk P, Aarntzen EH, Punt CJ, de V, I, Figdor CG. Maximizing dendritic cell migration in cancer immunotherapy. Expert Opin Biol Ther 2008; 8 (7): 865-74.
40. Gattinoni L, Powell DJ, Jr., Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006; 6 (5): 383-93.
41. Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 2008; 222: 129-44.
42. Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia 2007; 21(9): 1859-74.
43. Assudani DP, Horton RB, Mathieu MG, McArdle SE, Rees RC. The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines. Cancer Immunol Immunother 2007; 56(1): 70-80.
44. Zeng G. MHC class II-restricted tumor antigens recognized by CD4+ T cells: new strategies for cancer vaccine design. J Immunother 2001; 24(3): 195-204.
45. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008; 112(5): 1557-69.
46. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8(4): 247-58.
47. Conroy H, Marshall NA, Mills KH. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 2008; 27 (2): 168-80.
48. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8 (1): 59-73.
49. Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A. Toward the harmonization of immune monitoring in clinical trials: Quo vadis? Cancer Immunol Immunother 2008; 57(3): 285-8.
50. Britten CM, Gouttefangeas C, Welters MJ, et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother 2008; 57 (3): 289-302.
51. Janetzki S, Panageas KS, Ben-Porat L, et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 2008; 57(3): 303-15.
52. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009; 27: 83-117.
53. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 2007; 12(21-22): 898-910.
54. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105 (8): 3051-7.
55. Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist 2008; 13 (Suppl 4): 16-25.
56. Brahmer RJ, Topalian S, Wollner I, et al. Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol 2009; 26(15):3006.
57. Sznol M, Hodi FS, Margolin K, et al. Phase I study of BMS663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol 2008; 26(15): 3008.
58. Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006; 12 (7 Pt 2): 2353s-2358s.
59. Frumento G, Piazza T, Di CE, Ferrini S. Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr Metab Immune Disord Drug Targets 2006; 6 (3): 233-7.
60. Andersen MH, Gehl J, Reker S, et al. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 2003; 13(6): 449-59.
61. Gajewski TF, Fallarino F, Ashikari A, Sherman M. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 2001; 7(3 Suppl): 895s-901s.
62. Vahdat LT, Cohen DJ, Zipin D, et al. Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-gamma after highdose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer. Bone Marrow Transplant 2007; 40 (3): 267-72.
63. Robak T. Interferon alpha in the treatment of chronic myelogenous leukemia. Arch Immunol Ther Exp (Warsz) 1998; 46 (6): 347-53.
64. Andorsky DJ, Timmerman JM. Interleukin-21: biology and application to cancer therapy. Expert Opin Biol Ther 2008; 8 (9): 1295-307.
65. Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 2005; 175 (4): 2261-9.
66. Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 2007; 7 (8): 1245-56.
67. Frumento G, Piazza T, Di CE, Ferrini S. Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr Metab Immune Disord Drug Targets 2006; 6 (3): 233-7.
68. Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006; 12 (4): 1260-9.
69. Nistico P, Capone I, Palermo B, et al. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer 2009; 124 (1): 130-9.
70. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202 (12): 1691-701.
71. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 3(1): 54-61.
72. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26(32): 5233-9.
73. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56 (5): 641-8.
74. Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev 2001; 35(2): 161-204.
75. Helmbach H, Rossmann E, Kern MA, Schadendorf D. Drugresistance in human melanoma. Int J Cancer 2001; 93(5): 617-22.
76. Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev 2001; 35(2): 161-204.
77. Shangary S, Johnson DE. Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family. Leukemia 2003; 17(8): 1470-81.
78. Kuo MT. Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2009; 11(1): 99-133.
79. Bruno RD, Njar VC. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem 2007; 15(15): 5047-60.
80. Hoos A, Parmiani G, Hege K, et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007; 30(1): 1-15.
81. Doehn C, Jocham D. Does adjuvant vitespen prevent recurrence in patients with locally advanced kidney cancer? Nat Clin Pract Urol 2008; 5(12): 644-5.
82. Wood C, Srivastava P, Bukowski R, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 2008; 372 (9633): 145-54.
83. Available from: http//:www.antigenics.com.-2009.
84. Higano CS, Corman JM, Smith DC, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008; 113(5): 975-84.
85. Available from: http//: www.cellgenesys.com. - 2009
86. Bok RA. Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015. Ther Clin Risk Manag 2008; 4(1): 79-85.
87. Available from; http\\www.dendreon.com. - 2009.
88. Amato RJ, Shingler W, Naylor S, et al. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial. Clin Cancer Res 2008; 14(22): 7504-10.
89. Elkord E, Dangoor A, Burt DJ, et al. Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Cancer Immunol Immunother 2009; 58 (10): 1657-67.
90. Available from: http//: www.oxfordbiomedica.co.uk. - 2009
91. Reinis M. BiovaxID, a personalized therapeutic vaccine against B-celllymphomas. Curr Opin Mol Ther 2008; 10(5): 526-34.
92. Available from: http//: www.biovest.com. - 2009
93. Available from: http//: www.favrille.com. 2009. Ref Type: Internet Communication
94. Available from: http//: www.genitope.com. 2009. Ref Type: Internet Communication
95. Wang E, Phan GQ, Marincola FM. T-cell-directed cancer vaccines: the melanoma model. Expert Opin Biol Ther 2001; 1(2): 277-90.
96. Cerundolo V, Hermans IF, Salio M. Dendritic cells: a journey from laboratory to clinic. Nat Immunol 2004; 5(1): 7-10.
97. Goldman B, DeFrancesco L. The cancer vaccine roller coaster. Nat Biotechnol 2009; 27(2): 129-39.